Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587171 · ClinicalTrials.gov registry record · Phase 3
Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia
A Phase 3 study, sponsored by Jaeb Center for Health Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT00587171: Clinical Trial Phase 3 study, sponsored by Jaeb Center for Health Research.
NCT00587171 is a Phase 3 study that was terminated before completion, run by Jaeb Center for Health Research. The registered enrollment target is 19 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587171, a Phase 3 study, was terminated before completion, sponsored by Jaeb Center for Health Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is comparing the effectiveness of patching combined with active vision therapy plus near activities versus patching combined with control vision therapy plus near activities for moderate amblyopia (20/40-20/100) in 7 to \<13 year olds. The primary outcome measure is the proportion of patients with visual acuity of 20/25 or better in the amblyopic eye at the 17-week masked exam. These patients will be considered treatment responders. The primary analysis will consist of a comparison between the 2 treatment groups of the proportion of treatment responders with adjustment for baseline visual acuity. Secondary outcomes are stereoacuity at the 17-week masked exam, mean improvement in visual acuity at the 17-week masked exam, and rate of improvement of visual acuity.
Primary Outcome
Visual acuity was measured with the electronic early treatment diabetic retinopathy (E-ETDRS) method and resulted in a letter score that could range from 0 to 97 letters, with 0 being the worst and 97 being the best.
Interventions
- DEVICE Patching
- PROCEDURE Near activities
- PROCEDURE Active vision therapy
- PROCEDURE Control vision therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Why NCT00587171 stopped before completion
NCT00587171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Patching is the first listed.
NCT00587171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00587171 about?
NCT00587171 is a clinical study titled "Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia". This study is comparing the effectiveness of patching combined with active vision therapy plus near activities versus patching combined with control vision therapy plus near activities for moderate amblyopia (20/40-20/100) in 7 to \<13 year olds. The primary outcome measure is the proportion of pat...
What is the current status of trial NCT00587171?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2008-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00587171?
The interventions under investigation include: Patching (DEVICE), Near activities (PROCEDURE), Active vision therapy (PROCEDURE), Control vision therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00587171?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00587171's enrollment target sits among peer trials
19 1969th of 2000 higher than 31 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia